184 related articles for article (PubMed ID: 22996670)
1. Microemulsion-based oxyresveratrol for topical treatment of herpes simplex virus (HSV) infection: physicochemical properties and efficacy in cutaneous HSV-1 infection in mice.
Sasivimolphan P; Lipipun V; Ritthidej G; Chitphet K; Yoshida Y; Daikoku T; Sritularak B; Likhitwitayawuid K; Pramyothin P; Hattori M; Shiraki K
AAPS PharmSciTech; 2012 Dec; 13(4):1266-75. PubMed ID: 22996670
[TBL] [Abstract][Full Text] [Related]
2. Topical cream-based oxyresveratrol in the treatment of cutaneous HSV-1 infection in mice.
Lipipun V; Sasivimolphan P; Yoshida Y; Daikoku T; Sritularak B; Ritthidej G; Likhitwitayawuid K; Pramyothin P; Hattori M; Shiraki K
Antiviral Res; 2011 Aug; 91(2):154-60. PubMed ID: 21669230
[TBL] [Abstract][Full Text] [Related]
3. Anti-herpes simplex virus (HSV-1) activity of oxyresveratrol derived from Thai medicinal plant: mechanism of action and therapeutic efficacy on cutaneous HSV-1 infection in mice.
Chuanasa T; Phromjai J; Lipipun V; Likhitwitayawuid K; Suzuki M; Pramyothin P; Hattori M; Shiraki K
Antiviral Res; 2008 Oct; 80(1):62-70. PubMed ID: 18565600
[TBL] [Abstract][Full Text] [Related]
4. Development of novel microemulsion-based topical formulations of acyclovir for the treatment of cutaneous herpetic infections.
Shishu ; Rajan S; Kamalpreet
AAPS PharmSciTech; 2009; 10(2):559-65. PubMed ID: 19504745
[TBL] [Abstract][Full Text] [Related]
5. Enhanced acyclovir delivery using w/o type microemulsion: preclinical assessment of antiviral activity using murine model of zosteriform cutaneous HSV-1 infection.
Kaur A; Sharma G; Gupta V; Ratho RK; Katare OP
Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):346-354. PubMed ID: 28403666
[TBL] [Abstract][Full Text] [Related]
6. Effect of topically applied resveratrol on cutaneous herpes simplex virus infections in hairless mice.
Docherty JJ; Smith JS; Fu MM; Stoner T; Booth T
Antiviral Res; 2004 Jan; 61(1):19-26. PubMed ID: 14670590
[TBL] [Abstract][Full Text] [Related]
7. Skin irritation and the inhibition effect on HSV-1 in vivo of penciclovir-loaded microemulsion.
Yu A; Guo C; Zhou Y; Cao F; Zhu W; Sun M; Zhai G
Int Immunopharmacol; 2010 Oct; 10(10):1305-9. PubMed ID: 20727429
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of orally administered Lobelia chinensis extracts on herpes simplex virus type 1 infection in BALB/c mice.
Kuo YC; Lee YC; Leu YL; Tsai WJ; Chang SC
Antiviral Res; 2008 Nov; 80(2):206-12. PubMed ID: 18621082
[TBL] [Abstract][Full Text] [Related]
9. Influence of the treatment protocol upon the in vivo efficacy of cidofovir (HPMPC) and of acyclovir (ACV) formulations in topical treatment of cutaneous HSV-1 infection in hairless mice.
Afouna MI; Mehta SC; Ghanem AH; Higuchi WI; Kern ER; DeClercq E; El-Shattawy HH
J Pharm Sci; 1999 May; 88(5):530-4. PubMed ID: 10229644
[TBL] [Abstract][Full Text] [Related]
10. Sodium lauryl sulfate increases the efficacy of a topical formulation of foscarnet against herpes simplex virus type 1 cutaneous lesions in mice.
Piret J; Désormeaux A; Cormier H; Lamontagne J; Gourde P; Juhász J; Bergeron MG
Antimicrob Agents Chemother; 2000 Sep; 44(9):2263-70. PubMed ID: 10952566
[TBL] [Abstract][Full Text] [Related]
11. Formulation design of microemulsion for dermal delivery of penciclovir.
Zhu W; Yu A; Wang W; Dong R; Wu J; Zhai G
Int J Pharm; 2008 Aug; 360(1-2):184-90. PubMed ID: 18541394
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).
Snoeck R; Andrei G; Gérard M; Silverman A; Hedderman A; Balzarini J; Sadzot-Delvaux C; Tricot G; Clumeck N; De Clercq E
Clin Infect Dis; 1994 Apr; 18(4):570-8. PubMed ID: 8038312
[TBL] [Abstract][Full Text] [Related]
13. Topical treatment of cutaneous herpes simplex virus-1 infection in mice with a specially formulated caffeine gel (Cafon).
Yamamura J; Koyasu M; Sato H; Kurokawa M; Yoshida Y; Amahabu Y; Shiraki K
J Dermatol Sci; 1996 Apr; 12(1):50-5. PubMed ID: 8740461
[TBL] [Abstract][Full Text] [Related]
14. Effect of Azone upon the in vivo antiviral efficacy of cidofovir or acyclovir topical formulations in treatment/prevention of cutaneous HSV-1 infections and its correlation with skin target site free drug concentration in hairless mice.
Afouna MI; Fincher TK; Zaghloul AA; Reddy IK
Int J Pharm; 2003 Mar; 253(1-2):159-68. PubMed ID: 12593946
[TBL] [Abstract][Full Text] [Related]
15. In vivo anti-herpes simplex virus activity of a sulfated derivative of Agaricus brasiliensis mycelial polysaccharide.
Cardozo FT; Larsen IV; Carballo EV; Jose G; Stern RA; Brummel RC; Camelini CM; Rossi MJ; Simões CM; Brandt CR
Antimicrob Agents Chemother; 2013 Jun; 57(6):2541-9. PubMed ID: 23507287
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Cafon gel on cutaneous infection with herpes simplex virus (HSV)-2 and acyclovir-resistant HSV in mice.
Yoshida Y; Yamamura J; Sato H; Koyasu M; Obara Y; Sekiguchi H; Kawana T; Shiraki K
J Dermatol Sci; 1996 Dec; 13(3):237-41. PubMed ID: 9023706
[TBL] [Abstract][Full Text] [Related]
17. Pathogenicity and response to topical antiviral therapy in a murine model of acyclovir-sensitive and acyclovir-resistant herpes simplex viruses isolated from the same patient.
Lebel A; Boivin G
J Clin Virol; 2006 Sep; 37(1):34-7. PubMed ID: 16781887
[TBL] [Abstract][Full Text] [Related]
18. Topical treatment with BV-araU of immunosuppressed and immunocompetent shaved mice cutaneously infected with herpes simplex virus type 1.
Ijichi K; Ashida N; Varia S; Machida H
Antiviral Res; 1993 May; 21(1):47-57. PubMed ID: 8391248
[TBL] [Abstract][Full Text] [Related]
19. Fabrication of acyclovir-loaded flexible membrane vesicles (FMVs): evidence of preclinical efficacy of antiviral activity in murine model of cutaneous HSV-1 infection.
Sharma G; Thakur K; Setia A; Amarji B; Singh MP; Raza K; Katare OP
Drug Deliv Transl Res; 2017 Oct; 7(5):683-694. PubMed ID: 28801835
[TBL] [Abstract][Full Text] [Related]
20. Value of the dorsal cutaneous guinea pig model in selecting topical antiviral formulations for the treatment of recurrent herpes simplex type 1 disease.
Poli G; Dall'Ara P; Binda S; Santus G; Poli A; Cocilovo A; Ponti W
Arzneimittelforschung; 2001; 51(5):433-8. PubMed ID: 11413746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
